[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100477066":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":42,"centralContacts":46,"locations":53,"responsibleParty":281,"collaborators":283,"id":289,"slug":51,"hasResults":290,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":51,"eligibilityCriteria":294,"healthyVolunteers":290,"sex":295,"minAge":296,"maxAge":297,"enrollmentInfo":298,"targetDuration":51,"studyType":301,"phases":302,"briefSummary":304,"conditions":305,"keywords":307,"overallStatus":56,"whyStopped":51,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":322},{"fullName":5,"class":6},"Hospital Israelita Albert Einstein","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Standard Chemoradiation","ACTIVE_COMPARATOR","Traditional radiation therapy with a target of 45 Gy in 25 1.8Gy fractions with concurrent weekly cisplatin 40mg\u002Fm2\u002Fweek or carboplatin AUC 2\u002Fweek",[13],"Radiation: Chemoradiation",{"label":15,"type":16,"description":17,"interventionNames":18},"Immunotherapy","EXPERIMENTAL","4 cycles of induction therapy with nivolumab 1mg\u002Fkg and ipilimumab 3mg\u002Fkg every 3 weeks followed by traditional radiation therapy with a target of 45 Gy in 25 1.8Gy fractions with concurrent weekly cisplatin 40mg\u002Fm2\u002Fweek (or carboplatin AUC 2\u002Fweek) with concurrent nivolumab 240mg every 2 weeks.",[19,20,13],"Drug: Nivolumab 40 mg in 4 ml Injection","Drug: Ipilimumab 200 MG in 40 ML Injection",[22,29,35],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","Nivolumab 40 mg in 4 ml Injection","Nivolumab 1mg\u002Fkg every 3 weeks for 4 cycles prior to radiation and 240mg every 2 weeks with concurrent radiation",[15],[28],"Opdivo",{"type":23,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"Ipilimumab 200 MG in 40 ML Injection","Ipilimumab 3mg\u002Fkg every 3 weeks for 4 cycles prior to radiation",[15],[34],"Yervoy",{"type":36,"name":37,"description":38,"armGroupLabels":39,"otherNames":40},"RADIATION","Chemoradiation","Radiation to a dose of 45Gy over 25 1.8Gyfractions and brachytherapy with concurrent weekly cisplatin 40mg\u002Fm2\u002Fw or carboplatin AUC 2\u002Fw",[15,9],[41],"Cisplatin-based chemoradiation",[43],{"name":44,"affiliation":5,"role":45},"Fernando Maluf, MD","PRINCIPAL_INVESTIGATOR",[47],{"name":48,"role":49,"phone":50,"phoneExt":51,"email":52},"Diogo Bugano, MD","CONTACT","+55-11-2151-0240",null,"diogo.gomes@einstein.br",[54,74,90,108,125,142,158,175,192,209,225,241,256,270],{"facility":55,"status":56,"city":57,"state":58,"zip":59,"country":60,"cosmosGeoPoint":61,"geoPoint":66,"contacts":67},"CRIO -Centro Regional Integrado de Oncologia","RECRUITING","Fortaleza","Ceará","60335-480","Brazil",{"type":62,"coordinates":63},"Point",[64,65],-38.54306,-3.71722,{"lat":65,"lon":64},[68,72],{"name":69,"role":49,"phone":70,"phoneExt":51,"email":71},"Eduardo Cronemberger","+55(85)3286-5934","cronmeberger.eduardo@gmail.com",{"name":73,"role":45,"phone":51,"phoneExt":51,"email":51},"Eduardo Cronemberger, MD",{"facility":75,"status":56,"city":76,"state":77,"zip":78,"country":60,"cosmosGeoPoint":79,"geoPoint":83,"contacts":84},"Clinica AMO","Salvador","Estado de Bahia","41810-011",{"type":62,"coordinates":80},[81,82],-38.49096,-12.97563,{"lat":82,"lon":81},[85,89],{"name":86,"role":49,"phone":87,"phoneExt":51,"email":88},"Aknar Calabrich","+55(71)3021-8735","aknar@clinicaamo.com.br",{"name":86,"role":45,"phone":51,"phoneExt":51,"email":51},{"facility":91,"status":92,"city":93,"state":94,"zip":95,"country":60,"cosmosGeoPoint":96,"geoPoint":100,"contacts":101},"Hospital das Clinicas da UFMG","NOT_YET_RECRUITING","Belo Horizonte","Minas Gerais","30130-100",{"type":62,"coordinates":97},[98,99],-43.93778,-19.92083,{"lat":99,"lon":98},[102,106],{"name":103,"role":49,"phone":104,"phoneExt":51,"email":105},"Angélica Nogueira","+55(31)3307-9255","angélica.onco@uol.com.br",{"name":107,"role":45,"phone":51,"phoneExt":51,"email":51},"Angélica Nogueira, MD",{"facility":109,"status":92,"city":110,"state":111,"zip":112,"country":60,"cosmosGeoPoint":113,"geoPoint":117,"contacts":118},"Hospital Erasto Gaertner","Curitiba","Paraná","81520-060",{"type":62,"coordinates":114},[115,116],-49.27306,-25.42778,{"lat":116,"lon":115},[119,123],{"name":120,"role":49,"phone":121,"phoneExt":51,"email":122},"Reitan Ribeiro","+55(41)3361-5195","reitanribeiro@hotmail.com",{"name":124,"role":45,"phone":51,"phoneExt":51,"email":51},"Reitan Ribeiro, MD",{"facility":126,"status":56,"city":127,"state":128,"zip":129,"country":60,"cosmosGeoPoint":130,"geoPoint":134,"contacts":135},"Multi Oncoclinicas Recife","Recife","Pernambuco","50070-460",{"type":62,"coordinates":131},[132,133],-34.88111,-8.05389,{"lat":133,"lon":132},[136,140],{"name":137,"role":49,"phone":138,"phoneExt":51,"email":139},"Carla Rameri","+55(81)2122-4792","carla.rameri.de.azevedo@gmail.com",{"name":141,"role":45,"phone":51,"phoneExt":51,"email":51},"Carla Rameri, MD",{"facility":143,"status":92,"city":144,"state":145,"zip":146,"country":60,"cosmosGeoPoint":147,"geoPoint":151,"contacts":152},"Hospital São Lucas - PUCRS","Porto Alegre","Rio Grande do Sul","90610-001",{"type":62,"coordinates":148},[149,150],-51.23019,-30.03283,{"lat":150,"lon":149},[153,157],{"name":154,"role":49,"phone":155,"phoneExt":51,"email":156},"Fernanda Damian","+55(51)3320-3039","fernandadamian@yahoo.com.br",{"name":154,"role":45,"phone":51,"phoneExt":51,"email":51},{"facility":159,"status":56,"city":160,"state":161,"zip":162,"country":60,"cosmosGeoPoint":163,"geoPoint":167,"contacts":168},"Universidade Federal de Roraima","Boa Vista","Roraima","69310-000",{"type":62,"coordinates":164},[165,166],-60.67333,2.81972,{"lat":166,"lon":165},[169,173],{"name":170,"role":49,"phone":171,"phoneExt":51,"email":172},"Allex Jardim","+55(95)3224-4712","allex.j.fonseca@gmail.com",{"name":174,"role":45,"phone":51,"phoneExt":51,"email":51},"Allex Jardim, MD, PhD",{"facility":176,"status":92,"city":177,"state":178,"zip":179,"country":60,"cosmosGeoPoint":180,"geoPoint":184,"contacts":185},"CEPON - Florianópolis","Florianópolis","Santa Catarina","88034-000",{"type":62,"coordinates":181},[182,183],-48.54917,-27.59667,{"lat":183,"lon":182},[186,190],{"name":187,"role":49,"phone":188,"phoneExt":51,"email":189},"Anne Schmitz","+55(48)3331-1553","anneschmitz@uol.com.br",{"name":191,"role":45,"phone":51,"phoneExt":51,"email":51},"Anne Schmitz, MD",{"facility":193,"status":92,"city":194,"state":195,"zip":196,"country":60,"cosmosGeoPoint":197,"geoPoint":201,"contacts":202},"Hospital de Amor","Barretos","São Paulo","14784-400",{"type":62,"coordinates":198},[199,200],-48.56778,-20.55722,{"lat":200,"lon":199},[203,207],{"name":204,"role":49,"phone":205,"phoneExt":51,"email":206},"Maria Fernanda Biazzotto","+55(17)3321-6638","nandabiazotto@hotmail.com",{"name":208,"role":45,"phone":51,"phoneExt":51,"email":51},"Maria Fernanca Biazzotto, MD",{"facility":210,"status":92,"city":211,"state":195,"zip":212,"country":60,"cosmosGeoPoint":213,"geoPoint":217,"contacts":218},"Hospital De Base de São José do Rio Preto - CIP São José","São José do Rio Preto","15090-000",{"type":62,"coordinates":214},[215,216],-49.37944,-20.81972,{"lat":216,"lon":215},[219,223],{"name":220,"role":49,"phone":221,"phoneExt":51,"email":222},"João Daniel","+55(17)3201-5054","joaodcguedes@gmail.com",{"name":224,"role":45,"phone":51,"phoneExt":51,"email":51},"João Daniel, MD",{"facility":226,"status":92,"city":227,"state":51,"zip":228,"country":60,"cosmosGeoPoint":229,"geoPoint":233,"contacts":234},"INCA - Instituto Nacional do Cancer","Rio de Janeiro","20230-130",{"type":62,"coordinates":230},[231,232],-43.18223,-22.90642,{"lat":232,"lon":231},[235,239],{"name":236,"role":49,"phone":237,"phoneExt":51,"email":238},"Adriana Melo","+55(21)3207-2985","andreia.melo@inca.gov.br",{"name":240,"role":45,"phone":51,"phoneExt":51,"email":51},"Andreia Melo, MD",{"facility":242,"status":92,"city":195,"state":51,"zip":243,"country":60,"cosmosGeoPoint":244,"geoPoint":248,"contacts":249},"AC Camargo Cancer Center","01509-001",{"type":62,"coordinates":245},[246,247],-46.63611,-23.5475,{"lat":247,"lon":246},[250,254],{"name":251,"role":49,"phone":252,"phoneExt":51,"email":253},"Natasha Carvalho","+55(11)2189-5021","natasha.pandolfi@accamargo.org.br",{"name":255,"role":45,"phone":51,"phoneExt":51,"email":51},"Natasha Carvalho, MD",{"facility":257,"status":56,"city":195,"state":51,"zip":258,"country":60,"cosmosGeoPoint":259,"geoPoint":261,"contacts":262},"Hospital Municipal Vila Santa Catarina","04378-500",{"type":62,"coordinates":260},[246,247],{"lat":247,"lon":246},[263,268],{"name":264,"role":49,"phone":265,"phoneExt":266,"email":267},"Ana Lucia Neves","2151-1223","0","ana.neves@einstein.br",{"name":269,"role":45,"phone":51,"phoneExt":51,"email":51},"Henrique A Helber, MD",{"facility":5,"status":56,"city":195,"state":51,"zip":271,"country":60,"cosmosGeoPoint":272,"geoPoint":274,"contacts":275},"05652-900",{"type":62,"coordinates":273},[246,247],{"lat":247,"lon":246},[276,278,280],{"name":277,"role":49,"phone":51,"phoneExt":51,"email":51},"Fernando Maluf",{"name":279,"role":49,"phone":51,"phoneExt":51,"email":52},"Diogo Bugano",{"name":277,"role":45,"phone":51,"phoneExt":51,"email":51},{"type":282,"investigatorFullName":51,"investigatorTitle":51,"investigatorAffiliation":51,"oldNameTitle":51,"oldOrganization":51},"SPONSOR",[284,287],{"name":285,"class":286},"Bristol-Myers Squibb","INDUSTRY",{"name":288,"class":286},"Brava","100477066",false,"NCT05492123","Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer","Randomized Phase II Study to Evaluate Induction Nivolumab-Ipilimumab, Followed by Nivolumab With Chemoradiotherapy Versus Chemoradiotherapy for Advanced Cervical Cancer","Inclusion Criteria:\n\n* Female participants older than 18 years\n* Documented evidence of cervical adenocarcinoma or squamous carcinoma FIGO Stage IB2-IB3 node positive or Stage IIB-IVA\n* No prior chemotherapy, immune checkpoint inhibitors or radiotherapy for cervical cancer\n* WHO\u002FECOG performance status of 0-1\n* At least 1 lesion, not previously irradiated, that qualifies as a RECIST 1.1 Target Lesion at baseline.\n\nExclusion Criteria:\n\n* Diagnosis of small cell (neuroendocrine) histology cervical cancer\n* Intent to administer a fertility-sparing treatment regimen\n* Undergone a previous hysterectomy\n* Evidence of metastatic disease per RECIST 1.1 including lymph nodes ≥15 mm (short axis) above the L1 cephalad body or outside the planned radiation field.\n* History of allogeneic organ transplantation\n* Active or prior documented autoimmune or inflammatory disorders\n* Uncontrolled intercurrent illness\n* History of another primary malignancy and active primary immunodeficiency\n* Patients with active infection\n\nLaboratory values that fall into:\n\n1. WBC count (WBC) \\\u003C 2000\u002FμL ;\n2. Neutrophil count \\\u003C 1500\u002FμL;\n3. Platelet count \\\u003C 100 x 103\u002FμL;\n4. Hemoglobin level \\\u003C 9.0 g\u002FdL;\n5. Serum creatinine \\> 1.5 x upper limit of normal (ULN) unless creatinine clearance is\n\n   ≥ 40 mL\u002Fmin (measured or calculated using the Cockcroft-Gault formula);\n6. Aspartate aminotransferase (AST)\u002FAlanine aminotransferase (ALT): \\> 3.0 x ULN;\n7. Total bilirubin \\> 1.5 x ULN (except participants with Gilbert Syndrome who must have a total bilirubin level of \\\u003C 3.0 x ULN);\n8. Any positive test result for hepatitis B virus or hepatitis C virus that indicates the presence of the virus, for example, positive Hepatitis B surface antigen (HBsAg, Australia antigen) or Hepatitis C antibodies (anti- HCV) positive (unless the HCV-RNA is negative).\n\n   * Participants with a condition requiring systemic treatment or with corticosteroids (\\>10 mg daily of a prednisone equivalent) or other immunosuppressive drugs within 14 days of initiating study treatment.\n   * Pregnant or breastfeeding woman","FEMALE","18 Years","95 Years",{"count":299,"type":300},112,"ESTIMATED","INTERVENTIONAL",[303],"PHASE2","A total of 112 patients with locally advanced cervical cancer will be randomized 1:1 to standard therapy with cisplatin-based chemoradiation or nivolumab-ipilimumab induction followed by cisplatin-based chemoradiation. The primary outcome will be 3-year disease-free survival.",[306],"Uterine Cervical Neoplasms",[306,308,309,37,310,311,312,15],"Nivolumab","Ipilimumab","Anti-PD1","Anti-PDL1","Anti-CTLA4","2024-01-03",{"date":315,"type":316},"2024-01-05","ACTUAL",{"date":318,"type":316},"2022-08-30",{"date":320,"type":300},"2028-03-31",{"name":5,"class":6},14]